Berlin, Germany & Seoul, South Korea, 3 December 2025 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in South Korea. Eckert & Ziegler will supply SK Biopharmaceuticals with Actinium-225 (Ac-225) to accelerate their research and development activities in radiopharmaceutical therapies.

SK Biopharmaceuticals’ development pipeline includes SKL35501, an innovative radiopharmaceutical labeled with Ac-225 with potential in the treatment of multiple types of cancer, including colorectal, breast, pancreatic, and head and neck cancers. By securing reliable supply of the alpha emitting radioisotope from Eckert & Ziegler, the company will be able to drive forward this as well as further programs from their expanding pipeline.

“We are happy to support SK Biopharmaceuticals with our supply of GMP compliant Ac-225 in their promising preclinical and clinical programs,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Ac-225 remains one of the most in-demand radioisotopes for the development of next-generation radiopharmaceuticals, and we are pleased to contribute to the advancement of these cancer therapies.”

“Securing a stable supply of Ac-225, the key source material for radiopharmaceutical therapy, is a prerequisite for success. We are pleased to have concluded this agreement with Eckert & Ziegler, a reliable provider with long time track record for high-quality radioisotopes to be used in pharma,” said Donghoon Lee, CEO of SK Biopharmaceuticals. “Building on our proactive global partnership and diversified supply chain, we will take a major step forward in advancing into the global oncology treatment market.”

Eckert & Ziegler reliably supplies Gallium-68, Lutetium-177, Yttrium-90, and Actinium-225 in GMP quality to leading pharmaceutical companies and research institutions worldwide. With expertise in radioisotope production as well as global logistics and CDMO services, the company is committed to continuously supporting the development and delivery of innovative radiopharmaceuticals.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About SK Biopharmaceuticals 
SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea’s second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals, and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME’s 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit https://sk-inc.com/en/main/mainpage.aspx. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

SK Biopharmaceuticals Public Relations Team
skbp.pr@sk.com